(S)-3-acetamidoquinuclidine | 134869-59-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 奎宁环
• 英文名称: (S)-3-acetamidoquinuclidine
• 英文别名: S-N-(quinuclidinyl-3)-acetamide；N-[(3S)-1-azabicyclo[2.2.2]octan-3-yl]acetamide
• CAS: 134869-59-3
• 化学式: C₉H₁₆N₂O
• 分子量: 168.239
• InChiKey: USNCYWOZRFYMOR-SECBINFHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.89
• 拓扑面积：
  32.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (S)-3-acetamidoquinuclidine 、 溴甲苯 以 丙酮 为溶剂， 以72%的产率得到(S)-N-benzyl-3-acetamidoqinuclidinium bromide
  参考文献：
  名称：

  Odzak, Renata; Primozic, Ines; Tomic, Srdanka, Croatica Chemica Acta, 2007, vol. 80, # 1, p. 101 - 107

  摘要：

  DOI：
• 作为产物：
  描述：

  乙酸酐 、 S-3-氨基奎宁环二盐酸盐 反应 3.0h， 以89%的产率得到(S)-3-acetamidoquinuclidine
  参考文献：
  名称：

  Odzak, Renata; Primozic, Ines; Tomic, Srdanka, Croatica Chemica Acta, 2007, vol. 80, # 1, p. 101 - 107

  摘要：

  DOI：

文献信息

• Dihydrothienopyrimidines for the Treatment of Inflammatory Diseases
  申请人：Pouzet Pascale

  公开号：US20080096882A1

  公开（公告）日：2008-04-24

  The invention relates to new dihydrothienopyrimidine of formula 1, as well as pharmacologically acceptable salts, diastereomers, enantiomers, racemates, hydrates or solvates thereof, wherein X is SO or SO 2 , but preferably SO, and wherein R 1 , R 2 and R 3 have the meanings given in the description, and which are suitable for the treatment of respiratory or gastrointestinal complaints or diseases, inflammatory diseases of the joints, skin or eyes, diseases of the peripheral or central nervous system or cancers, as well as pharmaceutical compositions which contain these compounds.

  该发明涉及公式1的新二氢噻吡嘧啶，以及其药理学上可接受的盐、对映体、旋光异构体、消旋体、水合物或溶剂合物，其中X为SO或SO2，但最好为SO，R1、R2和R3在描述中给出的含义，并且适用于治疗呼吸道或胃肠道疾病、关节、皮肤或眼睛的炎症性疾病、外周或中枢神经系统疾病或癌症，以及含有这些化合物的药物组合物。
• PREPARATION OF DIHYDROTHIENO [3, 2-D] PYRIMIDINES AND INTERMEDIATES USED THEREIN
  申请人：Frutos Rogelio

  公开号：US20100222585A1

  公开（公告）日：2010-09-02

  The invention relates to improved methods of preparing dihydrothienopyrimidines of formula 1, and intermediates thereof, (I) wherein X is SO or SO 2 , preferably SO, and wherein R A , R 1 , R 2 , R 3 , R 4 and R 5 have the meanings given in the description. The methods according to this invention are more suitable for large-scale synthesis of said pounds than prior methods because the new synthetic process avoids distillation and chromatographic purification between steps and results in a higher overall yield of the desired product.

  本发明涉及改进的制备式1的二氢噻唑嘧啶化合物及其中间体的方法，其中X为SO或SO2，优选为SO，RA、R1、R2、R3、R4和R5具有所述描述中给出的含义。本发明的方法比先前的方法更适用于大规模合成所述化合物，因为新的合成过程避免了蒸馏和色谱纯化步骤，从而得到所需产物的总收率更高。
• RING-FUSED HETEROCYCLIC COMPOUND
  申请人：Kyowa Hakko Kirin Co., Ltd.

  公开号：US20150284384A1

  公开（公告）日：2015-10-08

  The ring-fused heterocyclic compound or a pharmaceutically acceptable salt thereof according to the present invention has a T-type calcium channel regulatory effect, and is useful, for example, as a medicament for treating and/or preventing pruritus. The present invention provides a ring-fused heterocyclic compound represented by the following general formula (I) or a pharmaceutically acceptable salt thereof and the like which has a T-type calcium channel regulatory effect and is useful as a therapeutic and/or preventive agent for pruritus, and the like. [wherein, R 1 represents optionally substituted lower alkyl and the like, R 2 represents optionally substituted lower alkyl and the like, R 3 represents the formula (II): (wherein, n represents 0 or 1, R 3a represents a hydrogen atom and the like, R 3b represents a hydrogen atom and the like, and R 3c represents a hydrogen atom and the like) and the like, Q represents a hydrogen atom and the like, and W 1 represents a nitrogen atom and the like, W 2 represents a nitrogen atom and the like]

  根据本发明，环融合杂环化合物或其药学上可接受的盐具有T型钙通道调节作用，例如，可用作治疗和/或预防瘙痒的药物。本发明提供了由以下一般式(I)或其药学上可接受的盐等表示的环融合杂环化合物，具有T型钙通道调节作用，可用作治疗和/或预防瘙痒等疾病的治疗和/或预防剂。其中，R1代表可选取代的低碳基等，R2代表可选取代的低碳基等，R3代表公式(II)：（其中，n代表0或1，R3a代表氢原子等，R3b代表氢原子等，R3c代表氢原子等）等，Q代表氢原子等，W1代表氮原子等，W2代表氮原子等。
• CONDENSED RING HETEROCYCLIC COMPOUND
  申请人：Kyowa Hakko Kirin Co., Ltd.

  公开号：EP2881394A1

  公开（公告）日：2015-06-10

  The ring-fused heterocyclic compound or a pharmaceutically acceptable salt thereof according to the present invention has a T-type calcium channel regulatory effect, and is useful, for example, as a medicament for treating and/or preventing pruritus. The present invention provides a ring-fused heterocyclic compound represented by the following general formula (I) or a pharmaceutically acceptable salt thereof and the like which has a T-type calcium channel regulatory effect and is useful as a therapeutic and/or preventive agent for pruritus, and the like. [wherein, R1 represents optionally substituted lower alkyl and the like, R2 represents optionally substituted lower alkyl and the like, R3 represents the formula (II): (wherein, n represents 0 or 1, R3a represents a hydrogen atom and the like, R3b represents a hydrogen atom and the like, and R3c represents a hydrogen atom and the like) and the like, Q represents a hydrogen atom and the like, and W1 represents a nitrogen atom and the like, W2 represents a nitrogen atom and the like]

  根据本发明的环融杂环化合物或其药学上可接受的盐具有 T 型钙通道调节作用，例如可用作治疗和/或预防瘙痒症的药物。本发明提供了由以下通式（I）代表的环融杂环化合物或其药学上可接受的盐等，该化合物具有 T 型钙通道调节作用，可用作治疗和/或预防瘙痒症等的药物。 [其中，R1 代表任选取代的低级烷基等，R2 代表任选取代的低级烷基等，R3 代表式 (II)： (其中，n 代表 0 或 1，R3a 代表氢原子等，R3b 代表氢原子等，R3c 代表氢原子等）等，Q 代表氢原子等，W1 代表氮原子等，W2 代表氮原子等]。
• PREPARATION OF S-(-)- AND R-(+)-N-(QUINUCLIDINYL-3)-AMIDE
  申请人：CHIRON LABORATORIES A/S

  公开号：EP0594569A1

  公开（公告）日：1994-05-04